Research Papers:

The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma

Jun Wang, Ping Zhang, Jie Zhong, Mingyue Tan, Jifu Ge, Le Tao, Yakui Li, Yemin Zhu, Lifang Wu, Jianxin Qiu and Xuemei Tong _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:27142-27157. https://doi.org/10.18632/oncotarget.8382

Metrics: PDF 2564 views  |   HTML 3251 views  |   ?  


Jun Wang1, Ping Zhang2, Jie Zhong2, Mingyue Tan1, Jifu Ge1, Le Tao1, Yakui Li2, Yemin Zhu2, Lifang Wu2, Jianxin Qiu1 and Xuemei Tong2

1 Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2 Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence to:

Xuemei Tong, email:

Jianxin Qiu, email:

Keywords: PFKP, aerobic glycolysis, proliferation, clear cell renal cell carcinoma

Received: September 06, 2015 Accepted: March 14, 2016 Published: March 25, 2016


Metabolic alterations underlying clear cell renal cell carcinoma (ccRCC) progression include aerobic glycolysis, increased pentose phosphate pathway activity and reduced oxidative phosphorylation. Phosphofructokinase (PFK), a key enzyme of the glycolytic pathway, has L, M, and P isoforms with different tissue distributions. The mRNA level of the platelet isoform of phosphofructokinase (PFKP) is reported to be up-regulated in ccRCC patients. However, it remains unclear whether PFKP plays an important role in promoting aerobic glycolysis and macromolecular biosynthesis to support cell proliferation in ccRCC. Here we found that the up-regulated PFKP became the predominant isoform of PFK in human ccRCC. Suppression of PFKP not only impaired cell proliferation by inducing cell cycle arrest and apoptosis, but also led to decreased glycolysis, pentose phosphate pathway and nucleotide biosynthesis, accompanied by activated tricarboxylic acid cycle in ccRCC cells. Moreover, we found that p53 activation contributed to cell proliferation and metabolic defects induced by PFKP knockdown in ccRCC cells. Furthermore, suppression of PFKP led to reduced ccRCC tumor growth in vivo. Our data indicate that PFKP not only is required for metabolic reprogramming and maintaining cell proliferation, but also may provide us with a valid target for anti-renal cancer pharmaceutical agents.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8382